Biocept Executes Preferred Provider Agreement With Scripps Health Plan Expanding Patient Coverage For Its Liquid Biopsy Platform

SAN DIEGO, Aug. 7, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered into a preferred provider agreement with Scripps Health Plan. Scripps integrates its award-winning providers and facilities with a robust health plan, enabling large businesses to offer employees access to comprehensive care through a single source. With this and other health plan agreements, over 190 million covered lives have in-network access to Biocept's liquid biopsy platform.

Biocept Logo (PRNewsFoto/Biocept, Inc.)

"Scripps is a highly recognized and respected name in the San Diego area and we are pleased that our novel liquid biopsy service is now available to cancer patients in their health plan system," said Biocept's President and CEO Michael Nall. "Our Target Selector tests can be used to improve treatment outcomes by helping physicians rapidly obtain the actionable information they need to design personalize treatment plans for their cancer patients. Our liquid biopsy tests are now available on an in-network basis to millions of patients throughout the United States."

About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer.  Biocept's patented Target Selector liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit

Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to improve the outcomes of cancer patients, the utility and effectiveness of our intellectual property protections, the financial impact of new contracts, and our ability to increase the number of products or services provided or the value of the Company, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this news release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC at

View original content with multimedia:

SOURCE Biocept, Inc.

Back to news